 |
|
The Effects of Ceruletide in Schizophrenia
Daniel W. Hommer, MD;
David Pickar, MD;
Alec Roy, MB;
Philip Ninan, MD;
John Boronow, MD;
Steven M. Paul, MD
Arch Gen Psychiatry. 1984;41(6):617-619.
Abstract
| |
• Eight neuroleptic-resistant schizophrenic patients were treated with ceruletide diethylamine, a cholecystokininlike peptide, in a placebo-controlled, double-blind, cross-over study. Ceruletide or placebo was administered intramuscularly twice a day for four consecutive days while patients received a constant dose of fluphenazine hydrochloride. Cholecystokinin octapeptide was also administered to four different schizophrenic patients in a double-blind, cross-over study. Cholecystokinin or placebo was administered as a slow intravenous infusion daily for four days. There were no changes in either the positive or negative symptoms of schizophrenia between the periods of placebo, ceruletide, or cholecystokinin administration. Furthermore, there was no tendency for the patients' conditions to either improve or worsen during the course of ceruletide or cholecystokinin treatment. In contrast to previous reports from uncontrolled studies, cholecystokininlike peptides appear to be devoid of antipsychotic properties when administered parenterally.
Author Affiliations
From the National Institute of Mental Health, Clinical Neuroscience Branch, Bethesda, Md. Dr Ninan is now with the Department of Psychiatry, Emory University Clinic, Atlanta. Dr Boronow is now with the Sheppard Pratt Hospital, Baltimore.
Footnotes
Accepted for publication Feb 22, 1984.
Reprint requests to National Institute of Mental Health, Clinical Neuroscience Branch, NIH Bldg 10, Room 4N214, 9000 Rockville Pike, Bethesda, MD 20205 (Dr Hommer).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Deconstructing Schizophrenia: An Overview of the Use of Endophenotypes in Order to Understand a Complex Disorder
Braff et al.
Schizophr Bull 2007;33:21-32.
ABSTRACT
| FULL TEXT
|
